Histologic Response Up With Benralizumab for Eosinophilic Esophagitis

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, June 26, 2024 -- Benralizumab yields a greater histologic response than placebo for patients with eosinophilic esophagitis, but does not affect dysphagia symptoms, according to a study published in the June 27 issue of the New England Journal of Medicine.

Marc E. Rothenberg, M.D., Ph.D., from the Leiden University Medical Center in the Netherlands, and colleagues conducted a phase 3 randomized trial involving patients aged 12 to 65 years with symptomatic and histologically active eosinophilic esophagitis. Participants were randomly assigned to receive benralizumab (30 mg) or placebo every four weeks (104 and 107 patients, respectively).

The researchers found that more patients had a histologic response to benralizumab than placebo at 24 weeks (87.4 versus 6.5 percent). However, no significant between-group difference was seen for the change from baseline in the Dysphagia Symptom Questionnaire score. Furthermore, no substantial between-group difference was seen in the change from baseline in the Eosinophilic Esophagitis Endoscopic Reference Score. Overall, 64.1 and 61.7 percent of patients in the benralizumab and placebo groups, respectively, reported adverse events.

"Benralizumab resulted in a higher incidence of histologic response than placebo but did not result in a greater reduction in dysphagia symptoms," the authors write. "This trial calls into question the clinical relevance of monitoring eosinophilic esophagitis for treatment effect solely on the basis of the degree of eosinophilic inflammation."

Several authors disclosed ties to AstraZeneca, which manufactures benralizumab and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-06-27 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords